Observational studyPloS one2026
Analysis of serum calprotectin levels in ménière's patients and investigation of its effect on disease severity.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis prospective observational study aimed to evaluate serum calprotectin levels in patients with definite Ménière's Disease (MD) and to investigate their association with symptom duration and disease severity. MATERIALS AND
methodsThirty-nine patients (16 males, 23 females; mean age 37.2 ± 11.9 years) diagnosed with definite MD according to the AAO-HNS criteria and 28 age- and sex-matched healthy controls (14 males, 14 females; mean age 39.2 ± 13.3 years) without vestibular or auditory complaints were included. Individuals with active infection, autoimmune or chronic inflammatory disease, recent antibiotic or steroid use, or other otologic pathologies were excluded. Serum calprotectin levels were measured during an acute vertigo attack in the MD group and once in controls. Between-group differences and correlations with clinical variables were analyzed using appropriate parametric and non-parametric tests.
resultsMean serum calprotectin levels during acute attack were significantly higher in the MD group than in controls (1031 ± 364 vs. 611 ± 231 ng/mL, p < 0.001). Within the MD group, calprotectin levels showed a strong positive correlation with symptom duration (Spearman's ρ = 0.914, p < 0.001). In patients with MD, calprotectin levels decreased significantly after treatment, from 1031 ± 364 to 582 ± 339 ng/mL (mean difference 449 ng/mL, 95% CI 353-545; t(38) = 9.46, p < 0.001; Cohen's d = 1.51), indicating a large effect size.
conclusionPatients with Ménière's Disease exhibit elevated serum calprotectin levels during acute attacks, which correlate strongly with symptom duration and decrease significantly after treatment. These findings suggest that calprotectin may be a potential inflammatory biomarker associated with disease burden and treatment response in MD; however, longitudinal studies with larger cohorts are needed to determine its diagnostic and prognostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.